Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Lutembacher Syndrome : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Multimedia
References

Related Articles
Atrial Septal Defect

Mitral Stenosis

Patent Foramen Ovale

Pulmonary Hypertension, Primary

Pulmonary Hypertension, Secondary

Tricuspid Stenosis




Patient Education
Click here for patient education.



Author: Kamran Riaz, MD, Clinical Assistant Professor, Department of Internal Medicine, Section of Cardiology, Wright State University School of Medicine

Kamran Riaz is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, American Society of Echocardiography, Ohio State Medical Association, and Royal College of Physicians

Coauthor(s): Alan D Forker, MD, Professor of Medicine, Program Director of Cardiovascular Fellowship, MidAmerica Heart Institute, University of Missouri at Kansas City School of Medicine; Director, Outpatient Lipid Diabetes Research Center, MidAmerica Heart Institute of Saint Luke's Hospital

Editors: Gary E Sander, MD, PhD, Professor, Department of Internal Medicine, Division of Cardiology, Tulane University Health Sciences Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Marschall S Runge, MD, PhD, Marion Covington Distinguished Professor of Medicine, Vice Dean for Clinical Affairs, Chairman, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine; Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital; Park W Willis IV, MD, Sarah Graham Distinguished Professor of Medicine and Pediatrics, University of North Carolina at Chapel Hill School of Medicine

Author and Editor Disclosure

Synonyms and related keywords: Lutembacher's syndrome, ASD, mitral valve lesion, atrial septal defect, mitral stenosis, left-to-right atrial shunt, mitral insufficiency, mixed lesion, congenital atrial septal defect, iatrogenic atrial septal defect, congenital mitral stenosis, acquired mitral stenosis, rheumatic mitral valve disease, mitral valvuloplasty, restenosis of the mitral valve, rheumatic heart disease, rheumatic mitral stenosis, pulmonary congestion, rheumatic fever, right-sided heart failure, right heart failure, pulmonary venous congestion, atrial septal defect closure, mitral commissurotomy closure, mitral valve replacement, atrial arrhythmias

Background

Lutembacher syndrome is defined as a combination of mitral stenosis and a left-to-right shunt at the atrial level. Typically, the left-to-right shunt is an atrial septal defect (ASD) of the ostium secundum variety. Both these defects, ASD and mitral stenosis, can be either congenital or acquired.

The definition of Lutembacher syndrome has undergone many changes. The earliest description in medical literature is found in a letter written by anatomist Johann Friedrich Meckel to Albrecht von Haller in 1750. In 1916, Lutembacher described his first case of this syndrome, involving a 61-year-old woman, and he attributed the mitral valvular lesion to congenital mitral stenosis. Because the mitral stenosis was, in fact, rheumatic in etiology, the syndrome was defined eventually as a combination of congenital ASD and acquired, almost always rheumatic, mitral stenosis.

In the current era of mitral valvuloplasty for acquired mitral stenosis, however, residual iatrogenic ASD secondary to transseptal puncture is more common than congenital ASD, as is the combination of ASD and mitral stenosis. Although this syndrome is generally defined as mitral stenosis in combination with ASD, some have argued to define the syndrome as a combination of ASD and any mitral valve lesion, ie, mitral stenosis, mitral insufficiency, or mixed lesion. Currently, any combination of ASD, congenital or iatrogenic, and mitral stenosis, congenital or acquired, is referred as Lutembacher syndrome.

Pathophysiology

Mitral stenosis can be either congenital, as initially described, or acquired in origin, most commonly due to rheumatic mitral valve disease. Isolated mitral stenosis is now known to be a rare congenital disorder, and most cases of mitral stenosis initially thought to be congenital were, in fact, caused by rheumatic mitral valve disease.

Similarly, understanding of the etiology of ASD as associated with Lutembacher syndrome has evolved over time. Initially, high left atrial pressure due to mitral stenosis was thought to stretch open the patent foramen ovale (PFO), causing left-to-right shunt and providing another outlet for the left atrium. Now ASD in this syndrome, like mitral stenosis, is recognized as being either congenital or acquired, as already described.

Acquired ASD is almost always iatrogenic, either intentional or as a complication of a percutaneous interventional procedure. The incidence of left-to-right atrial shunt following mitral valvuloplasty is estimated at 11-12%. Although most of these ASDs are small and hemodynamically insignificant, some can be large enough to have hemodynamic consequences, especially in patients who develop restenosis of the mitral valve.

The hemodynamic effects of this syndrome are a result of the interplay between the relative effects of ASD and mitral stenosis. In its initial description, the ASD was typically large in Lutembacher syndrome, thus providing another route for blood flow. Iatrogenic ASDs tend to be smaller but still may be hemodynamically significant. The direction of blood flow is determined largely by the compliance of left and right ventricles. Normally, the right ventricle is more compliant than the left ventricle.

As a result, in the presence of mitral stenosis, blood flows to the right atrium through the ASD instead of going backward into the pulmonary veins, thus avoiding pulmonary congestion. This happens at the cost of progressive dilatation and, ultimately, failure of the right ventricle and reduced blood flow to the left ventricle. Development of Eisenmenger syndrome or irreversible pulmonary vascular disease is very uncommon in the presence of large ASD and high left atrial pressure because of mitral stenosis.

The term reverse Lutembacher syndrome is sometimes used to describe those rare cases in which a predominant right-to-left shunt develops owing to development of severe tricuspid stenosis.

Frequency

United States

The true incidence of the syndrome is not clearly known. Although mitral stenosis is encountered in 4% of patients with an ASD, congenital mitral stenosis itself is very rare, accounting for only 0.6% of congenital heart disease cases at autopsy. The incidence of ASD in patients with mitral stenosis is 0.6-0.7%. In one US study, the combination was found in 5 of 25,000 autopsies. The syndrome was diagnosed more frequently in the past for the following reasons:

  • Without echocardiography, the combination of mid diastolic murmur, actually due to increased blood flow across the tricuspid valve, and systolic murmur of ASD led to a mistaken diagnosis of Lutembacher syndrome.
  • The prevalence of both rheumatic heart disease and mitral stenosis was higher in western developed countries before the antibiotic era. With the decline in the frequency of rheumatic fever, the prevalence of mitral stenosis has decreased and so has diagnosis of the syndrome. A history of rheumatic fever is frequently absent.

  • Even though ASD may be underdiagnosed in the United States, the combination of ASD and mitral stenosis may not be evident on physical examination and for that reason is best confirmed by echocardiography.

International

Although the exact prevalence of Lutembacher syndrome is not known, it is probably higher in areas where rheumatic heart disease is still common.

Mortality/Morbidity

No definite data are available. Mortality and morbidity rates are related to the relative severity of the individual lesions.

Race

No data are available regarding racial distribution of the condition.

Sex

Lutembacher syndrome is more common in females than males. Part of the reason is the higher incidence of both congenital ASD and rheumatic mitral stenosis in females.

Age

This syndrome can present at any age. Cases have been diagnosed in the seventh decade of life. Lutembacher's original case was a 61-year-old woman who had been pregnant 7 times. In the current era of balloon mitral valvuloplasty and development of ASD, the age of presentation may change.



History

Patients may remain asymptomatic for many years. Symptoms are mainly due to the ASD, and signs and symptoms vary according to the size of the ASD. With a large ASD, symptoms of pulmonary congestion, typical of isolated mitral stenosis, do not appear until late in the course of the disease. Conversely, these symptoms may appear early if the patient has an associated small ASD or develops pulmonary hypertension for other reasons. Patients with large ASD and moderate-to-severe mitral stenosis have signs and symptoms due mainly to right ventricular overload and right-sided heart failure, while patients with a small ASD and moderate-to-severe mitral stenosis have signs and symptoms of pulmonary congestion typical of mitral stenosis.

  • The patient may or may not have a history of rheumatic fever.
  • Fatigue and reduced exercise tolerance result from decreased systemic blood flow. The presence of mitral stenosis and left-to-right blood flow in diastole through the ASD reduces the forward flow of blood into the left ventricle, thereby reducing systemic blood flow and leading to fatigue and poor exercise tolerance.
  • Palpitations are a common presenting symptom. Because of the augmented left-to-right shunt caused by higher left atrial pressure and mitral stenosis, both atria are dilated. This predisposes patients to atrial arrhythmias; atrial fibrillation is very common.
  • Weight gain, ankle edema, right upper quadrant pain, and ascites are seen more commonly in patients with large ASD. Such symptoms are manifestations of the development of right-sided heart failure. A chronically increased left-to-right blood flow at the atrial level can eventually lead to right-sided heart failure.
  • Paroxysmal nocturnal dyspnea, orthopnea, and hemoptysis are signs of pulmonary venous congestion. Such symptoms are caused by mitral stenosis and are seen less frequently in Lutembacher syndrome than in isolated mitral stenosis. They are more common in patients with small ASD and are probably more common in patients who develop reverse Lutembacher syndrome. In some patients with large pulmonary blood flow due to a large left-to-right shunt, orthopnea can develop because of decreased compliance of the lungs.

Physical

Physical examination reveals signs due to the ASD and mitral stenosis, which are modified because of the presence of both lesions in the same patient.

  • Arterial pulse
  • Jugular venous pulse
    • Distended jugular veins, even in the absence of right heart failure
    • Large a waves when sinus rhythm is present
    • Increased right ventricular pressure a more important determinant than equalization of atrial pressures in increasing jugular venous pressure
  • Precordial examination
    • Left parasternal lift, caused by transmitted right ventricular and pulmonary artery impulse, is common.
    • Left ventricular impulse is unimpressive, owing to reduced filling of the left ventricle secondary to mitral stenosis.
    • A tapping apex impulse due to the palpable, loud first heart sound of mitral stenosis may be present.
    • A diastolic thrill at the apex is unusual.
  • Heart sounds
    • Loud first heart sound, opening snap, and a mitral early-to-mid diastolic murmur are the classic auscultatory findings of mitral stenosis and are variably present.
      • Reduced transmitral pressure gradient resulting from decompression of the left atrium through the ASD and displacement of the left ventricular apex due to a large right ventricle attenuate these classic findings of mitral stenosis.
      • Development of pulmonary hypertension and, consequently, an increase in right atrial and left atrial pressures may increase transmitral pressure gradient and bring out these auscultatory findings, but this phenomenon is canceled by further dilatation of the right ventricle, thus obscuring the left ventricular apex.
    • The second heart sound (S2) may be widely split for 2 reasons. Increased right heart flow of ASD can result in late closure of the pulmonary component of the S2, and decreased left ventricular and aortic flow, secondary to mitral stenosis and ASD, can cause early closure of the aortic component of S2.
  • Additional heart sounds and murmurs
    • Third and fourth heart sounds of right ventricular origin may be audible at the left sternal border and are louder with inspiration.
    • Systolic murmurs are due to the following:
      • ASD along the upper left parasternal area - Typically a flow murmur due to increased flow across the pulmonic valve
      • Tricuspid regurgitation along the lower left parasternal area - Due to the displaced tricuspid valve secondary to right ventricular dilatation; common
      • Holosystolic murmur at the left parasternal area due to tricuspid regurgitation - Usually increases with inspiration (Carvallo sign), which differentiates it from ASD and mitral regurgitation
    • Mid diastolic murmurs are due to the following:
      • Increased flow across the tricuspid valve due to ASD or accompanying tricuspid stenosis, best heard at left lower sternal border or at apex for reasons already mentioned
      • Mitral stenosis, best heard with stethoscope bell at apex after exercise and with patient in left lateral position
    • Continuous murmur in the lower right sternal area is due to continuous shunting of blood across a small ASD in the presence of severe mitral stenosis. This is an unusual finding on physical examination.
  • Abdomen: Ascites and hepatomegaly may be noted in the presence of right heart failure.
  • Extremities: Ankle edema may be present in the presence of right-sided heart failure.

Causes

  • Mitral stenosis is mostly rheumatic in origin.
  • Congenital mitral stenosis is very rare.
  • ASD is either congenital or iatrogenic.



Atrial Septal Defect
Mitral Stenosis
Patent Foramen Ovale
Pulmonary Hypertension, Primary
Pulmonary Hypertension, Secondary
Tricuspid Stenosis


Imaging Studies

  • Chest radiographs
    • Pulmonary plethora due to left-to-right shunt
    • Mild left atrial enlargement
    • Right ventricular enlargement
    • Pulmonary artery enlargement
    • Mitral valve calcification late in life
    • Pulmonary vascular congestion and marked left atrial enlargement in cases of severe mitral stenosis and small ASD
  • Transthoracic or transesophageal echocardiography - May show the following during various stages of the disease:
    • Two-dimensional (see Media files 1-2)
      • Large left atrium
      • Large right atrium and ventricle
      • Enlarged pulmonary artery
      • ASD
      • Stenotic mitral valve
    • Color flow and Doppler imaging: This confirms the presence and evaluates the severity of ASD, mitral stenosis and mitral regurgitation, tricuspid regurgitation, and pulmonary pressure (see Media files 3-8).
    • Doppler pressure half-time method: This usually overestimates the mitral valve area. Because of the presence of ASD, the transmitral pressure gradient is generally lower than expected for the degree of the mitral stenosis, thereby falsely underestimating the pressure half-time and overestimating the mitral valve area. On the other hand, planimetry and the Doppler continuity equation method should give an accurate assessment of the mitral valve area in Lutembacher syndrome.
  • Transesophageal echocardiography - May be required to separate the PFO from the ASD and to fully delineate the anatomy

Other Tests

  • Electrocardiogram
    • Rhythm
      • Sinus rhythm
      • Atrial fibrillation
    • P wave morphology
      • Tall, broad, or bifid in lead II with a deep negative force in V1 suggesting biatrial enlargement
      • Isolated left atrial abnormality more indicative of a more severe mitral stenosis with small ASD
    • QRS morphology and axis
      • Right-axis deviation
      • Complete or incomplete right bundle-branch block or right ventricular hypertrophy

Procedures

Cardiac catheterization is not performed routinely to confirm the diagnosis. It can be used, however, to evaluate the severity of the ASD, detect reversible pulmonary hypertension, measure the mitral valve area by the Gorlin formula, and evaluate the presence of coronary artery disease in high-risk patients.



Medical Care

  • Symptomatic relief
    • Right-sided heart failure - Diuretics
    • Atrial arrhythmias - Digoxin, beta-blockers, and calcium channel blockers used mainly for rate control, while amiodarone and sotalol used not only for rate control but also for conversion into and maintenance of normal sinus rhythm
  • Subacute bacterial endocarditis (SBE) prophylaxis: Patients with Lutembacher syndrome, unlike those with isolated ASD, are at high risk for SBE owing to associated mitral stenosis; thus, SBE prophylaxis is warranted.

Surgical Care

Until recently, surgery was the only definite curative treatment available and involved closure of the ASD and mitral commissurotomy or mitral valve replacement.

  • Percutaneous closure of ASD and mitral balloon valvuloplasty
    • Percutaneous closure of the ASD with a clamshell device and mitral valvuloplasty provides a nonsurgical approach to correct these defects. Although mitral valvuloplasty has been performed for several decades, percutaneous closure of an ASD with a device represents a still-developing technology.
    • As already described, mitral valvuloplasty alone can be complicated by development of ASD secondary to transseptal puncture performed as a part of the procedure.
  • Indications for surgery or percutaneous intervention
    • ASD with a Qp/Qs ratio of more than 1.5
    • Moderate-to-severe mitral stenosis
    • Any degree of pulmonary hypertension, except individuals with irreversible pulmonary hypertension (Eisenmenger syndrome, see below)
  • Surgery is now performed early rather than late because the rates of heart failure and cardiac arrhythmia increase with age. Patients with pulmonary hypertension should demonstrate reversibility of pulmonary vascular resistance prior to surgical (or percutaneous) correction of ASD. Patients with pulmonary hypertension and irreversibly increased pulmonary vascular resistance (ie, Eisenmenger physiology) invariably develop progressive right-sided heart failure after ASD closure and die.

Consultations

  • Cardiothoracic surgeon
  • Interventional cardiologist

Diet

Patients should adhere to a low-sodium diet.

Activity

Activity should be as tolerated by the patient.



The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Drug Category: Diuretics

These agents inhibit sodium and chloride reabsorption. They are used to treat right-sided heart failure.

Drug NameFurosemide (Lasix)
DescriptionIncreases excretion of water by interfering with chloride-binding cotransport system, which inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after previous dose, until desired diuresis occurs. When treating infants, titrate with 1-mg/kg/dose increments until satisfactory effect achieved.
Adult Dose20-80 mg/d PO/IV/IM; titrate up to 600 mg/d for severe edematous states
Pediatric Dose1-2 mg/kg/dose PO; not to exceed 6 mg/kg/dose; do not administer more often than q6h
1 mg/kg IV/IM slowly, under close supervision; not to exceed 6 mg/kg
ContraindicationsDocumented hypersensitivity; hepatic coma; anuria; severe electrolyte depletion
InteractionsMetformin decreases levels; interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; aminoglycosides increase risk of auditory toxicity—hearing loss of varying degrees may occur; may enhance anticoagulant activity of warfarin; may increase plasma levels and toxicity of lithium
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsPerform frequent serum electrolyte, carbon dioxide, glucose, creatinine, uric acid, calcium, and BUN determinations during first few months of therapy and periodically thereafter

Drug Category: Cardiac glycosides

These agents are used to treat atrial arrhythmias. They have both direct and indirect effects.

Drug NameDigoxin (Lanoxin)
DescriptionCardiac glycoside with direct inotropic effects in addition to indirect effects on cardiovascular system. Acts directly on cardiac muscle, increasing myocardial systolic contractions. Indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure.
Adult Dose0.125-0.375 mg PO qd
Pediatric Dose5-10 years: 20-35 mcg/kg PO
>10 years: 10-15 mcg/kg PO
Maintenance dose: 25-35% of PO loading dose
ContraindicationsDocumented hypersensitivity; beriberi heart disease; idiopathic hypertrophic subaortic stenosis; constrictive pericarditis; carotid sinus syndrome
InteractionsAlprazolam, benzodiazepines, bepridil, captopril, cyclosporine, propafenone, propantheline, quinidine, diltiazem, aminoglycosides, oral amiodarone, anticholinergics, diphenoxylate, erythromycin, felodipine, flecainide, hydroxychloroquine, itraconazole, nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol, tetracycline, tolbutamide, and verapamil may increase serum levels
Aminoglutethimide, antihistamines, cholestyramine, neomycin, penicillamine, aminoglycosides, oral colestipol, hydantoins, hypoglycemic agents, antineoplastic treatment combinations (including carmustine, bleomycin, methotrexate, cytarabine, doxorubicin, cyclophosphamide, vincristine, procarbazine), aluminum or magnesium antacids, rifampin, sucralfate, sulfasalazine, barbiturates, kaolin/pectin, and aspirin may decrease serum levels
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsHypokalemia may reduce positive inotropic effect and predispose patients to digitalis toxicity; IV calcium may produce arrhythmias in digitalized patients; hypercalcemia predisposes patients to digitalis toxicity, and hypocalcemia can make digoxin ineffective until serum calcium levels are normal; magnesium replacement therapy must be instituted in patients with hypomagnesemia to prevent digitalis toxicity; patients diagnosed with incomplete AV block may progress to complete block; caution in hypothyroidism, hypoxia, and acute myocarditis

Drug Category: Antibiotics, prophylactic

These agents provide prophylaxis for subacute bacterial endocarditis (SBE). Patients with Lutembacher syndrome are at high risk for SBE owing to associated mitral stenosis.

Drug NameCephalexin (Keflex)
DescriptionFirst-generation cephalosporin that inhibits bacterial replication by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls.

Resistance occurs by alteration of penicillin-binding proteins. Effective for treatment of infections caused by streptococcal or staphylococcal infection, including penicillinase-producing staphylococci. May use to initiate therapy when streptococcal or staphylococcal infection is suspected.

Used orally when outpatient management is indicated. Primarily active against skin flora, including Staphylococcus aureus.
Adult Dose2 g PO 1h before procedure

Pediatric Dose<30 kg: 50 mg/kg PO 1h before procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with aminoglycosides increases nephrotoxic potential
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeat therapy

Drug NameAmoxicillin (Amoxil, Trimox)
DescriptionInterferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. Used as prophylaxis in minor procedures.
Adult Dose2 g PO 1 h before procedure
Pediatric Dose<30 kg: 50 mg/kg PO 1 h before procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsReduces efficacy of oral contraceptives
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in renal impairment

Drug NameAmpicillin (Marcillin, Omnipen)
DescriptionFor prophylaxis in patients undergoing dental, oral, or respiratory tract procedures. Coadministered with gentamicin for prophylaxis in GI or genitourinary procedures.
Adult Dose2 g IV/IM 30 min prior to procedure
High-risk patients: 2 g ampicillin IV/IM plus 1.5 mg/kg gentamicin 30 min prior to procedure
Pediatric Dose<30 kg: 50-mg/kg IV/IM 30 min prior to procedure
High-risk patients: 50 mg/kg IV/IM ampicillin plus gentamicin 1.5 mg/kg 30 min prior to procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid and disulfiram elevate levels; allopurinol decreases effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction

Drug NameClindamycin (Cleocin)
DescriptionUsed in penicillin-allergic patients undergoing dental, oral, or respiratory tract procedures. Useful for treatment against streptococcal and most staphylococcal infections.
Adult Dose600 mg PO/IV 1 h prior to procedure
Pediatric Dose<30 kg: 10 mg/kg PO 1h before procedure; not to exceed 600 mg
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis
InteractionsIncreases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis

Drug NameGentamicin (Garamycin)
DescriptionAminoglycoside antibiotic for gram-negative coverage. Used in combination with both an agent against gram-positive organisms and one that covers anaerobes. Used in conjunction with ampicillin or vancomycin for prophylaxis in GI or genitourinary procedures.
Adult Dose1.5 mg/kg IV with 1-2 g ampicillin 30 min prior to procedure; not to exceed 80 mg
Pediatric Dose<30 kg: 2 mg/kg IV with ampicillin (50 mg/kg) 30 min prior to procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity; non–dialysis-dependent renal insufficiency
InteractionsOther aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; enhances effects of neuromuscular blocking agents, thus prolonged respiratory depression may occur; loop diuretics may increase auditory toxicity—possible irreversible hearing loss of varying degrees may occur (monitor regularly)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsNarrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment

Drug NameVancomycin (Vancocin)
DescriptionPotent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in treatment of septicemia and skin structure infections. Indicated for patients who cannot receive, or have failed to respond to, penicillins and cephalosporins or have infections with resistant staphylococci. Use CrCl to adjust dose in patients diagnosed with renal impairment. Used in conjunction with gentamicin for prophylaxis in patients with penicillin allergy undergoing GI or genitourinary procedures.
Adult DoseDental, oral, or upper respiratory tract surgery: 1 g IV, infused over 1 h, 1 h prior to procedure
GI/GU procedures: 1 g IV plus gentamicin, 1.5 mg/kg IV, infused over 1 h, 1 h prior to surgery
Pediatric DoseDental, oral, or upper respiratory tract surgery:
<30 kg: 20 mg/kg IV 1 h prior to procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsAnesthetic agents may cause erythema, histaminelike flushing, and anaphylactic reactions; taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; may increase effects of nondepolarizing muscle relaxants in neuromuscular blockade
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in renal failure, neutropenia; red man syndrome caused by too rapid IV infusion (dose given over a few min) but rarely happens when dose given over 2 h or in PO or IP form; red man syndrome not an allergic reaction

Drug NameErythromycin (EES, E-Mycin, Eryc)
DescriptionUsed for prophylaxis in patients with penicillin allergy undergoing dental, oral, or respiratory tract procedures.
Adult Dose1 g PO 1-2 h before procedure
Pediatric Dose<30 kg: 20 mg/kg PO 2 h prior to procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity; hepatic impairment
InteractionsMay increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; may increase risk of rhabdomyolysis with lovastatin and simvastatin
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsCaution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur

Drug NameCefazolin (Ancef)
DescriptionFirst-generation semisynthetic cephalosporins that arrest bacterial cell wall synthesis, inhibiting bacterial growth. Primarily active against skin flora, including Staphylococcus aureus.
Adult DoseCefazolin: 1 g IV/IM within 30 min before procedure
Pediatric Dose<30 kg: 25 mg/kg IV/IM within 30 min before procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsFurosemide or aminoglycosides may increase nephrotoxicity; probenecid prolongs effects; may yield false-positive urine-dip test for glucose
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameAzithromycin (Zithromax)
DescriptionMacrolide antibiotics which inhibit bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Adult Dose500 mg PO 1 h before procedure
Pediatric Dose<30 kg: 15 mg/kg PO 1 h before procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity; hepatic impairment; concurrent pimozide
InteractionsFluconazole, astemizole [recalled from US market], and pimozide increase toxicity; rifabutin or rifampin may decrease effects and increase GI adverse effects; may increase toxicity of anticoagulants, cyclosporine, tacrolimus, digoxin, omeprazole, carbamazepine, ergot alkaloids, triazolam, HMG CoA-reductase inhibitors; cisapride may cause cardiac arrhythmias; may increase plasma levels of certain benzodiazepines, prolonging CNS depression; disopyramide causes arrhythmias and increase in QTc intervals; omeprazole may increase plasma levels of both omeprazole and clarithromycin
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDo not administer with pimozide
Bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in hospitalized, geriatric, or debilitated patients; coadministration of clarithromycin with ranitidine or bismuth citrate not recommended with CrCl <25 mL/min; give half dose or increase dosing interval if CrCl <30 mL/min; diarrhea may be sign of pseudomembranous colitis

Drug NameCefadroxil
DescriptionFirst generation semisynthetic cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primarily active against skin flora, including Staphylococcus aureus.
Adult Dose2 g PO 1h before procedure
Pediatric Dose<30 kg: 50 mg/kg PO 1h before procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may decrease clearance of cephalosporins; aminoglycosides and furosemide may increase nephrotoxicity
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection

Drug NameClarithromycin (Biaxin)
DescriptionSemisynthetic macrolide antibiotic that reversibly binds to P site of 50S ribosomal subunit of susceptible organisms and may inhibit RNA-dependent protein synthesis by stimulating dissociation of peptidyl t-RNA from ribosomes, causing bacterial growth inhibition.
Adult Dose500 mg PO 1 h before procedure
Pediatric Dose<30 kg: 15 mg/kg PO 1 h before procedure
>30 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity; coadministration of pimozide
InteractionsToxicity increases with coadministration of fluconazole and pimozide; effects decrease and GI adverse effects may increase with coadministration of rifabutin or rifampin; may increase toxicity of anticoagulants, cyclosporine, tacrolimus, digoxin, carbamazepine, ergot alkaloids, triazolam, HMG-CoA reductase inhibitors

Plasma levels of certain benzodiazepines may increase, prolonging CNS depression; arrhythmias and increases in QTc intervals occur with disopyramide; coadministration with omeprazole may increase plasma levels of both agents; decreases metabolism of repaglinide, thus increasing serum levels and effects
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCoadministration with ranitidine or bismuth citrate is not recommended with CrCl <25 mL/min; give half dose or increase dosing interval if CrCl <30 mL/min; diarrhea may be sign of pseudomembranous colitis; superinfections may occur with prolonged or repeated antibiotic therapies

Drug Category: Antiarrhythmics

These agents alter the electrophysiologic mechanisms responsible for arrhythmia.

Drug NameAmiodarone (Cordarone)
DescriptionMay inhibit AV conduction and sinus node function. Prolongs action potential and refractory period in myocardium and inhibits adrenergic stimulation. Prior to administration, control ventricular rate and CHF (if present) with digoxin or calcium channel blockers.
Adult DoseLoading dose: 800-1600 mg/d PO in 1-2 doses for 1-3 wk, and decrease to 600-800 mg/d in 1-2 doses for 1 mo
Maintenance dose: 400 mg/d PO; alternatively, 150 mg (10 mL) IV over first 10 min, followed by 360 mg (200 mL) over next 6 h, and then 540 mg over next 18 h
Pediatric Dose10-15 mg/kg/d or 600-800 mg/1.73 m2/d PO for 4-14 d or until arrhythmia adequately controlled
ContraindicationsDocumented hypersensitivity; complete AV block and intraventricular conduction defects; concurrent ritonavir or sparfloxacin
InteractionsIncreases effect and blood levels of theophylline, quinidine, procainamide, phenytoin, methotrexate, flecainide, digoxin, cyclosporine, beta-blockers, and anticoagulants; ritonavir, sparfloxacin, and disopyramide increase cardiotoxicity; calcium channel blockers may cause additive effects and further decrease myocardial contractility; cimetidine may increase levels
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in thyroid or liver disease

Drug NameDiltiazem (Cardizem, Dilacor, Tiamate, Tiazac)
DescriptionDuring depolarization, inhibits calcium ions from entering slow channels and voltage-sensitive areas of vascular smooth muscle and myocardium.
Adult DoseAtrial fibrillation/flutter: 0.25 mg/kg IV bolus, followed by 0.35 mg/kg if necessary, followed by 5-15 mg/h for 24 h if needed
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; severe CHF; sick sinus syndrome; second- or third-degree AV block; hypotension (<90 mm Hg systolic)
InteractionsMay increase carbamazepine, digoxin, cyclosporine, and theophylline levels; amiodarone may cause bradycardia and decrease cardiac output; beta-blockers may increase cardiac depression; cimetidine may increase levels
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in impaired renal or hepatic function; may increase LFT levels, and hepatic injury may occur. Also to be used with caution in patients with ventricular dysfunction.

Drug NameVerapamil (Calan, Covera, Verelan, Isoptin)
DescriptionCan diminish PVCs associated with perfusion therapy and decrease risk of ventricular fibrillation and ventricular tachycardia. By interrupting reentry at AV node, can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardias (PSVT).
Adult DoseSupraventricular tachycardia: 5-10 mg IV over 2 min; may repeat 10 mg after 15-30 min
Atrial fibrillation/flutter: 240-320 mg PO daily in divided doses
Pediatric DoseSupraventricular tachycardia:
<1 year: 0.1-0.2 mg/kg IV; may repeat in 30 min if necessary, need continuous ECG monitoring
>1 year: 0.1-0.3 mg/kg IV; not to exceed 5 mg/dose; may repeat in 30 min if necessary
ContraindicationsDocumented hypersensitivity; severe CHF; sick sinus syndrome or second- or third-degree AV block; hypotension (<90 mm Hg systolic)
InteractionsMay increase carbamazepine, digoxin, and cyclosporine levels; amiodarone can cause bradycardia and decrease cardiac output; beta-blockers may increase cardiac depression; cimetidine may increase levels; may increase theophylline levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsHepatocellular injury may occur; transient elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have occurred (elevations have been transient and may disappear with continued verapamil treatment); monitor liver function periodically

Drug NameSotalol (Betapace)
DescriptionClass III anti-arrhythmic agent that blocks potassium channels, prolongs action potential duration (APD), and lengthens QT interval. Noncardiac selective beta-adrenergic blocker.
Adult Dose80 mg PO bid; increase dose gradually q2-3d to 240-320 mg/d
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; sinus bradycardia; second- and third-degree AV block
InteractionsAluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease bioavailability and plasma levels, possibly resulting in decreased pharmacologic effect; sparfloxacin, astemizole [recalled from US market], calcium channel blockers, quinidine, flecainide, and contraceptives may increase cardiotoxicity; digoxin, flecainide, acetaminophen, clonidine, epinephrine, nifedipine, prazosin, haloperidol, phenothiazines, and catecholamine-depleting agents increase toxicity
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsBeta-adrenergic blockade may decrease signs and symptoms of acute hypoglycemia and clinical signs of hyperthyroidism; abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm; withdraw drug slowly and monitor patient closely; caution in hypokalemia, peripheral vascular disease, hypomagnesemia, and CHF

Drug NameEsmolol (Brevibloc)
DescriptionExcellent drug for patients at risk for complications from beta-blockade (particularly those with reactive airway disease, mild-to-moderate LV dysfunction, and/or peripheral vascular disease). Short half-life of 8 min allows for titration to desired effect and quick discontinuation if needed.
Adult DoseLoading dose: 250-500 mcg/kg/min IV for 1 min followed by 4-min maintenance infusion of 50 mcg/kg/min; if adequate therapeutic effect not observed within 5 min, repeat loading dose and follow with maintenance infusion using increments of 50 mcg/kg/min (for 4 min); sequence may be repeated up to 4 times if needed; as desired heart rate is approached, omit loading infusion and reduce incremental dose of maintenance infusion to 25 mcg/kg/min or lower; interval between titration steps may be increased from 5-10 min if needed
Pediatric DoseNot established; suggested dose is 100-500 mcg/kg IV over 1 min
ContraindicationsDocumented hypersensitivity; uncompensated CHF, bradycardia, cardiogenic shock, and AV conduction abnormalities
InteractionsAluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease bioavailability and plasma levels, possibly resulting in decreased pharmacologic effect; sparfloxacin, astemizole [recalled from US market], calcium channel blockers, quinidine, flecainide, and contraceptives may increase cardiotoxicity; digoxin, flecainide, acetaminophen, clonidine, epinephrine, nifedipine, prazosin, haloperidol, phenothiazines, and catecholamine-depleting agents increase toxicity
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMay mask signs and symptoms of acute hypoglycemia and clinical signs of hyperthyroidism; symptoms of hyperthyroidism, including thyroid storm, may worsen when medication abruptly withdrawn; withdraw drug slowly and monitor patient closely



Further Inpatient Care

  • Daily intake and output measurements
  • Daily weight measurement
  • Observation for worsening signs and symptoms of right-sided heart failure
  • Evaluation and treatment of any arrhythmias
  • Evaluation for any fever or new murmurs

Further Outpatient Care

  • SBE prophylaxis
  • Surveillance for worsening signs or symptoms of heart failure
  • Periodic echocardiograms to assess the severity of mitral stenosis and the magnitude of left-to-right shunt and pulmonary artery pressure
  • Periodic assessment of the following:
    • BUN levels
    • Creatinine levels
    • Serum electrolyte levels in patients taking diuretics

In/Out Patient Meds

  • Diuretics
  • Digoxin
  • Beta-blockers, in selected cases

Transfer

  • Patients should be transferred to either a surgical team or an interventional cardiologist for definitive treatment.

Complications

  • Right-sided heart failure
  • Atrial arrhythmias
  • Pulmonary congestion
  • SBE

Prognosis

  • Prognosis is generally good for this condition. Patients have lived into their ninth decade without developing any cardiac symptoms. Women have had multiple pregnancies without complications.

Patient Education

  • Educate patients regarding the basic anatomical defects and physiological consequences of the disease.
  • Heart failure education should include the following:
    • Low-salt diet
    • Daily weighing
    • Early warning signs of worsening right or left heart failure
  • Bacterial endocarditis prophylaxis



Medical/Legal Pitfalls

  • Failure to diagnose the accompanying mitral stenosis with ASD
  • Failure to provide SBE prophylaxis advice
  • Failure to refer the patient at the proper time for definitive treatment
  • Failure to diagnose other causes of pulmonary hypertension



Media file 1:  Shown is a 2-dimensional transthoracic echocardiogram of a 74-year-old woman who presented with signs of right heart failure. Note severely dilated left atrium, calcified and thickened mitral valve leaflets, doming of the anterior mitral valve leaflet, mitral annular calcification, and reduced opening of the mitral valve.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 2:  Shown is a 2-dimensional transesophageal echocardiogram during diastole of a 74-year-old woman who presented with signs of right-sided heart failure. Note the thickened, narrowed, and calcified mitral valve apparatus and doming of the anterior leaflet of the mitral valve.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 3:  Color-flow imaging of a 74-year-old woman who presented with signs of right-sided heart failure on transthoracic echocardiogram; this illustrates an anteriorly directed jet of moderate mitral regurgitation.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 4:  Color-flow imaging (subcostal view) on transthoracic echocardiogram showing the left-to-right shunt across the atrial septum of a 74-year-old woman who presented with signs of right-sided heart failure.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 5:  Shown is a color-flow image during transesophageal echocardiography at the mitral valve level of a 74-year-old woman who presented with signs of right-sided heart failure. Note anteriorly directed jet of moderate-to-severe mitral regurgitation during systole.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 6:  Color-flow imaging during transesophageal echocardiography shows blood flow across the atrial septum in a 74-year-old woman who presented with signs of right-sided heart failure.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 7:  Seen here are Doppler measurements at the mitral inflow level of a 74-year-old woman who presented with signs of right-sided heart failure. Note the reduced E-A slope and a peak transmitral velocity giving rise to a peak transmitral gradient of 21 mm Hg.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 8:  Doppler measurement across the atrial septum reveals a peak velocity of 4 m/s of a 74-year-old woman who presented with signs of right-sided heart failure.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image



  • Ansari A, Maron BJ. Lutembacher's syndrome. Tex Heart Inst J. 1997;24(3):230-1. [Medline].
  • Chau EM, Lee CH, Chow WH. Transcatheter treatment of a case of Lutembacher syndrome. Catheter Cardiovasc Interv. May 2000;50(1):68-70. [Medline].
  • Chen CH, Lin SL, Hsu TL, Chen CC, Wang SP, Chang MS. Iatrogenic Lutembacher's syndrome after percutaneous transluminal mitral valvotomy. Am Heart J. Jan 1990;119(1):209-11. [Medline].
  • Cheng TO. Coexistent atrial septal defect and mitral stenosis (Lutembacher syndrome): An ideal combination for percutaneous treatment. Catheter Cardiovasc Interv. Oct 1999;48(2):205-6. [Medline].
  • Crawford MH. Iatrogenic Lutembacher's syndrome revisited. Circulation. Apr 1990;81(4):1422-4. [Medline].
  • Essop MR, Essop AR, Bedhesi S, Sareli PE. Cyanosis and clubbing in a patient with iatrogenic Lutembacher syndrome. Eur Heart J. Mar 1995;16(3):421-3. [Medline].
  • Gopala Raju AR, Cherian G, Alurkar VM, Krishnaswami S, John S. Electrocardiographic features in Lutembacher's syndrome. Indian J Chest Dis Allied Sci. Jul-Sep 1979;21(3):125-9. [Medline].
  • Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J. Jul 1991;12 Suppl B:55-60. [Medline].
  • Joseph G, Abhaichand Rajpal K, Kumar KP. Definitive percutaneous treatment of Lutembacher's syndrome. Catheter Cardiovasc Interv. Oct 1999;48(2):199-204. [Medline].
  • Kauffmann R, Bianchi C, Meruane J, Thumala A, Goich J. [Lutembacher's syndrome: clinical, echocardiographic and hemodynamic aspects in 6 cases]. Rev Med Chil. May 1987;115(5):433-9. [Medline].
  • Perloff JK. Atrial septal defect: Lutembacher syndrome. In: The Clinical Recognition of Congenital Heart Disease. 3rd ed. Philadelphia, Penn: WB Saunders Co; 1987:299-304.
  • Quash JA, Davia JE, de Castro CM, Bowen TE, Green DC. Echocardiography in Lutembacher's syndrome. Chest. Nov 1977;72(5):676-8. [Medline].
  • Ruiz CE, Gamra H, Mahrer P, Allen JW, O'Laughlin MP, Lau FY. Percutaneous closure of a secundum atrial septal defect and double balloon valvotomies of a severe mitral and aortic valve stenosis in a patient with Lutembacher's syndrome and severe pulmonary hypertension. Cathet Cardiovasc Diagn. Apr 1992;25(4):309-12. [Medline].
  • Sadaniantz A, Luttmann C, Shulman RS, et al. Acquired Lutembacher syndrome or mitral stenosis and acquired atrial septal defect after transseptal mitral valvuloplasty. Cathet Cardiovasc Diagn. Sep 1990;21(1):7-9. [Medline].
  • Shigenobu M, Sano S. Surgical indications and treatment of mitral valve disease associated with secundum atrial septal defect with special reference to left ventricular geometry and function. J Cardiovasc Surg (Torino). Dec 1994;35(6):469-74. [Medline].
  • Turner SA, Paulus R, Massumi A, Duncan JM, Hernandez G, Hall RJ. Variant of Lutembacher's syndrome with intact atrial septum. Am Heart J. Jan 1994;127(1):224-7. [Medline].
  • Vasan RS, Shrivastava S, Kumar MV. Value and limitations of Doppler echocardiographic determination of mitral valve area in Lutembacher syndrome. J Am Coll Cardiol. Nov 15 1992;20(6):1362-70. [Medline].
  • Wiedemann HR. Earliest description by Johann Friedrich Meckel, Senior (1750) of what is known today as Lutembacher syndrome (1916). Am J Med Genet. Oct 15 1994;53(1):59-64. [Medline].

Lutembacher Syndrome excerpt

Article Last Updated: Feb 6, 2008